Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)

Inclusion Criteria: * Subfoveal CNV secondary to AMD. * Central retinal (including lesion) thickness ≥ 300 µm as measured by Optical Coherence Tomography (OCT). * Early Treatment of Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity of 73 letters to 34 letters. Exclusion Criteria: * History of any vitreous hemorrhage within 4 weeks prior to Day 1. * Aphakia. * Significant subfoveal atrophy or scarring. * Prior treatment with the following in the study eye: * Subfoveal thermal laser therapy. * Submacular surgery or other surgical intervention for the treatment of AMD. * Extrafoveal laser coagulation treatment within 12 weeks prior to Day 1. * Photodynamic therapy (PDT) within 12 weeks prior to Visit 2 (Day 1). * Pegaptanib sodium (Macugen) within 8 weeks of Visit 2 (Day 1). * Juxtascleral steroids or anecortave acetate within 24 weeks (6 months) prior to Visit 2 (Day 1). * Intravitreal administration of triamcinolone acetonide or other steroids within 24 weeks prior to Visit 2 (Day 1), unless no visible residue of drug substance can be seen in the vitreous cavity using indirect ophthalmoscopy. * Prior systemic or intravitreal treatment with VEGF Trap, ranibizumab (Lucentis) or bevacizumab (Avastin). * Presence of any other condition or laboratory abnormality, which, in the opinion of the Investigator, would interfere with the assessment of disease status/progression or jeopardize the patient's appropriate participation in this Phase II study.